P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
L. J. Nastoupil,
S. O’Brien,
H. E. Holmes,
L. Dsouza,
D. Hart,
E. Matsuda,
T. Satterfield-Ledbetter,
J. Skoble,
E. Garner,
M. Bryan,
S. Kanner,
E. Li,
C. T. Thomas,
J. Essell
Affiliations
L. J. Nastoupil
1 Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston
S. O’Brien
2 Department of Hematology and Oncology, University of California Irvine, Irvine
H. E. Holmes
3 Oncology, Texas Oncology/Baylor Sammons Cancer Center, Dallas
L. Dsouza
1 Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston
D. Hart
4 Research, Oncology Hematology Care, Cincinnati
E. Matsuda
5 UCI Cancer Center, University of California Irvine, Irvine
T. Satterfield-Ledbetter
6 Clinical Oncology Research Coordination, Baylor Research Institution, Dallas
